News | August 08, 2022
Valiant Organics to start production of OAP and Pharma Intermediates
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
Under the PMBJP, till 30.06.2022, 8742 PMBJKs have been opened across the country including Government Hospitals and Government premises.
India exported Bulk Drugs/Drug Intermediates worth Rs. 33,320 crore in financial year 2021-22.
Strides is the first Indian company to get approval for the product.
The two generic drugs have been launched under the brand names Jankey & Sitenali.
The audit is part of the agency's inspection for three product applications filed and slated to be manufactured at this site.
The financial assistance by the centre is subject to a maximum limit of Rs.1000 crore per park
The product will be manufactured at Lupin's facility in Nagpur, India.
Subscribe To Our Newsletter & Stay Updated
